Leïla Heidsieck

The paper uses single-domain antibodies to investigate how different tau domains influence RNA-induced tau liquid-liquid phase separation, identifying a proline-rich domain as critical for condensation.

This paper develops a selective non-muscle myosin II inhibitor, MT-228, with high brain penetration and efficacy in preclinical models, offering therapeutic potential for diseases like stimulant use disorder.